Bridging With Percutaneous Devices: Tandem Heart and Impella · Bridging With Percutaneous Devices:...
Transcript of Bridging With Percutaneous Devices: Tandem Heart and Impella · Bridging With Percutaneous Devices:...
![Page 1: Bridging With Percutaneous Devices: Tandem Heart and Impella · Bridging With Percutaneous Devices: Tandem Heart and Impella DAVID A. BARAN, MD, FACC, FSCAI SYSTEM DIRECTOR, ADVANCED](https://reader033.fdocuments.in/reader033/viewer/2022051923/60113b9e924d623ac7210e23/html5/thumbnails/1.jpg)
Bridging With Percutaneous Devices: Tandem Heart and Impella
DAVID A. BARAN, MD, FACC, FSCAISYSTEM DIRECTOR, ADVANCED HEART FAILURE, TX AND MCSSENTARA HEART HOSPITALNORFOLK, VAPROFESSOR OF MEDICINE (CARDIOLOGY)EASTERN VIRGINIA MEDICAL SCHOOL
![Page 2: Bridging With Percutaneous Devices: Tandem Heart and Impella · Bridging With Percutaneous Devices: Tandem Heart and Impella DAVID A. BARAN, MD, FACC, FSCAI SYSTEM DIRECTOR, ADVANCED](https://reader033.fdocuments.in/reader033/viewer/2022051923/60113b9e924d623ac7210e23/html5/thumbnails/2.jpg)
Disclosures
• Research funding• Astellas, Abbott
• Consulting• TandemLife, Maquet, Luitpold
• Lectures• Otsuka, Novartis
![Page 3: Bridging With Percutaneous Devices: Tandem Heart and Impella · Bridging With Percutaneous Devices: Tandem Heart and Impella DAVID A. BARAN, MD, FACC, FSCAI SYSTEM DIRECTOR, ADVANCED](https://reader033.fdocuments.in/reader033/viewer/2022051923/60113b9e924d623ac7210e23/html5/thumbnails/3.jpg)
Outline
• Cardiogenic shock
• Tools• IAB• Impella
• 2.5• CP• 5.0
• Tandem Heart
• Conclusions
![Page 4: Bridging With Percutaneous Devices: Tandem Heart and Impella · Bridging With Percutaneous Devices: Tandem Heart and Impella DAVID A. BARAN, MD, FACC, FSCAI SYSTEM DIRECTOR, ADVANCED](https://reader033.fdocuments.in/reader033/viewer/2022051923/60113b9e924d623ac7210e23/html5/thumbnails/4.jpg)
Cardiogenic Shock: SHOCK trial definition
• Trial of AMI shock. Question of emergency revascularization vs initial medical stabilization
• End organ hypoperfusion due to cardiac failure• Cool extremities• Poor urine output or poor mental status
• SBP < 90 for at least 30 min
• Cardiac Index ≤ 2.2 with support
• LVEDP ≥ 15
Hochman J et al. NEJM 1999; 341: 625-634
![Page 5: Bridging With Percutaneous Devices: Tandem Heart and Impella · Bridging With Percutaneous Devices: Tandem Heart and Impella DAVID A. BARAN, MD, FACC, FSCAI SYSTEM DIRECTOR, ADVANCED](https://reader033.fdocuments.in/reader033/viewer/2022051923/60113b9e924d623ac7210e23/html5/thumbnails/5.jpg)
Shock Pathophysiology
Reynolds and Hochman. Circulation 2008; 117: 696-697
![Page 6: Bridging With Percutaneous Devices: Tandem Heart and Impella · Bridging With Percutaneous Devices: Tandem Heart and Impella DAVID A. BARAN, MD, FACC, FSCAI SYSTEM DIRECTOR, ADVANCED](https://reader033.fdocuments.in/reader033/viewer/2022051923/60113b9e924d623ac7210e23/html5/thumbnails/6.jpg)
Is Cardiogenic Shock Just a Pump Problem?
• Starts with the pump
• Hypoperfusion is associated with a cascade of events
• Vasoconstrictors utilized to raise blood pressure which worsens afterload, further reduces capillary perfusion due to drug-associated spasm
• Interrupting the vicious circle should help
![Page 7: Bridging With Percutaneous Devices: Tandem Heart and Impella · Bridging With Percutaneous Devices: Tandem Heart and Impella DAVID A. BARAN, MD, FACC, FSCAI SYSTEM DIRECTOR, ADVANCED](https://reader033.fdocuments.in/reader033/viewer/2022051923/60113b9e924d623ac7210e23/html5/thumbnails/7.jpg)
Tools to Address the Pump Problem
• Intra-aortic balloon pump
• LV- Aorta pump
• Left Atrium to Aorta / Femoral Artery pump
• Extracorporeal membrane oxygenation (VA ECMO)
• Right Sided Pumps
![Page 8: Bridging With Percutaneous Devices: Tandem Heart and Impella · Bridging With Percutaneous Devices: Tandem Heart and Impella DAVID A. BARAN, MD, FACC, FSCAI SYSTEM DIRECTOR, ADVANCED](https://reader033.fdocuments.in/reader033/viewer/2022051923/60113b9e924d623ac7210e23/html5/thumbnails/8.jpg)
Intra-Aortic Balloon Pump
• Different sizes depending on height of patient
• Inflates during diastole leading to diastolic augmentation and systolic unloading (lower afterload)
• Increased coronary perfusion
• Most common mechanical circulatory assist
• ? Increases cardiac output 0.5 L
![Page 9: Bridging With Percutaneous Devices: Tandem Heart and Impella · Bridging With Percutaneous Devices: Tandem Heart and Impella DAVID A. BARAN, MD, FACC, FSCAI SYSTEM DIRECTOR, ADVANCED](https://reader033.fdocuments.in/reader033/viewer/2022051923/60113b9e924d623ac7210e23/html5/thumbnails/9.jpg)
ACC AHA 2013 Guidelines
The use of intra-aortic balloon pump counterpulsation can be useful for patients with cardiogenic shock after STEMI who do not quickly stabilize with pharmacological therapy.
Alternative LV assist devices for circulatory support may be considered in patients with refractory cardiogenic shock.
I IIa IIb III
I IIa IIb III
![Page 10: Bridging With Percutaneous Devices: Tandem Heart and Impella · Bridging With Percutaneous Devices: Tandem Heart and Impella DAVID A. BARAN, MD, FACC, FSCAI SYSTEM DIRECTOR, ADVANCED](https://reader033.fdocuments.in/reader033/viewer/2022051923/60113b9e924d623ac7210e23/html5/thumbnails/10.jpg)
ESC 2016 Acute HF Guidelines
![Page 11: Bridging With Percutaneous Devices: Tandem Heart and Impella · Bridging With Percutaneous Devices: Tandem Heart and Impella DAVID A. BARAN, MD, FACC, FSCAI SYSTEM DIRECTOR, ADVANCED](https://reader033.fdocuments.in/reader033/viewer/2022051923/60113b9e924d623ac7210e23/html5/thumbnails/11.jpg)
SHOCK-2 IAB Trial
![Page 12: Bridging With Percutaneous Devices: Tandem Heart and Impella · Bridging With Percutaneous Devices: Tandem Heart and Impella DAVID A. BARAN, MD, FACC, FSCAI SYSTEM DIRECTOR, ADVANCED](https://reader033.fdocuments.in/reader033/viewer/2022051923/60113b9e924d623ac7210e23/html5/thumbnails/12.jpg)
SHOCK-2, 1 Year Results
Thiele H, et al. Lancet 2013; 382:1638-45
![Page 13: Bridging With Percutaneous Devices: Tandem Heart and Impella · Bridging With Percutaneous Devices: Tandem Heart and Impella DAVID A. BARAN, MD, FACC, FSCAI SYSTEM DIRECTOR, ADVANCED](https://reader033.fdocuments.in/reader033/viewer/2022051923/60113b9e924d623ac7210e23/html5/thumbnails/13.jpg)
IAB Pro / Con
• SHOCK-2 only addressed STEMI and only those randomized • Excluding the sickest patients where equipoise doesn’t exist
• 40 cc Balloon pumps (newer technology available)
• IAB is cheap (<$700-800) and readily usable without cath lab environment if needed
• Tolerant of minimal anticoagulation
• The expensive pumps are not superior!
![Page 14: Bridging With Percutaneous Devices: Tandem Heart and Impella · Bridging With Percutaneous Devices: Tandem Heart and Impella DAVID A. BARAN, MD, FACC, FSCAI SYSTEM DIRECTOR, ADVANCED](https://reader033.fdocuments.in/reader033/viewer/2022051923/60113b9e924d623ac7210e23/html5/thumbnails/14.jpg)
IAB
![Page 15: Bridging With Percutaneous Devices: Tandem Heart and Impella · Bridging With Percutaneous Devices: Tandem Heart and Impella DAVID A. BARAN, MD, FACC, FSCAI SYSTEM DIRECTOR, ADVANCED](https://reader033.fdocuments.in/reader033/viewer/2022051923/60113b9e924d623ac7210e23/html5/thumbnails/15.jpg)
Survival
![Page 16: Bridging With Percutaneous Devices: Tandem Heart and Impella · Bridging With Percutaneous Devices: Tandem Heart and Impella DAVID A. BARAN, MD, FACC, FSCAI SYSTEM DIRECTOR, ADVANCED](https://reader033.fdocuments.in/reader033/viewer/2022051923/60113b9e924d623ac7210e23/html5/thumbnails/16.jpg)
16
![Page 17: Bridging With Percutaneous Devices: Tandem Heart and Impella · Bridging With Percutaneous Devices: Tandem Heart and Impella DAVID A. BARAN, MD, FACC, FSCAI SYSTEM DIRECTOR, ADVANCED](https://reader033.fdocuments.in/reader033/viewer/2022051923/60113b9e924d623ac7210e23/html5/thumbnails/17.jpg)
Follow-Up Study
• 76 of the 150 patients had PA catheter monitoring prior and after the IAB
• “Responder” defined as ≥ 0.01 L/Min increase in cardiac output
• 60 / 76 (79%) responders
• 37 patients (49 % of the responders) had care escalated• 27 VAD’s (temporary or durable)• 10 direct to transplant
17
![Page 18: Bridging With Percutaneous Devices: Tandem Heart and Impella · Bridging With Percutaneous Devices: Tandem Heart and Impella DAVID A. BARAN, MD, FACC, FSCAI SYSTEM DIRECTOR, ADVANCED](https://reader033.fdocuments.in/reader033/viewer/2022051923/60113b9e924d623ac7210e23/html5/thumbnails/18.jpg)
Responders to IAB
18
Delta Cardiac Output: Responders vs. Non-Responders
-2
-1
0
1
2
3
4
5
Non-Responder
Responder
1.6 ± 1.1 L/min
Baran, et al. Cathet Card Diagnosis
![Page 19: Bridging With Percutaneous Devices: Tandem Heart and Impella · Bridging With Percutaneous Devices: Tandem Heart and Impella DAVID A. BARAN, MD, FACC, FSCAI SYSTEM DIRECTOR, ADVANCED](https://reader033.fdocuments.in/reader033/viewer/2022051923/60113b9e924d623ac7210e23/html5/thumbnails/19.jpg)
![Page 20: Bridging With Percutaneous Devices: Tandem Heart and Impella · Bridging With Percutaneous Devices: Tandem Heart and Impella DAVID A. BARAN, MD, FACC, FSCAI SYSTEM DIRECTOR, ADVANCED](https://reader033.fdocuments.in/reader033/viewer/2022051923/60113b9e924d623ac7210e23/html5/thumbnails/20.jpg)
Escalation of Care
20
4
6
3
3
6
21
12
21
0% 10% 20% 30% 40% 50% 60% 70% 80% 90% 100%
Bridge to OHT
Escalated to VAD
Unable to wean (no escalation)
Successful wean
Non-Responder Responder
![Page 21: Bridging With Percutaneous Devices: Tandem Heart and Impella · Bridging With Percutaneous Devices: Tandem Heart and Impella DAVID A. BARAN, MD, FACC, FSCAI SYSTEM DIRECTOR, ADVANCED](https://reader033.fdocuments.in/reader033/viewer/2022051923/60113b9e924d623ac7210e23/html5/thumbnails/21.jpg)
Impella Family
![Page 22: Bridging With Percutaneous Devices: Tandem Heart and Impella · Bridging With Percutaneous Devices: Tandem Heart and Impella DAVID A. BARAN, MD, FACC, FSCAI SYSTEM DIRECTOR, ADVANCED](https://reader033.fdocuments.in/reader033/viewer/2022051923/60113b9e924d623ac7210e23/html5/thumbnails/22.jpg)
USPELLA REGISTRY
154 patients undergoing PCI with CS
All Impella 2.5
CHF shock excluded
O’Neill et al. J Interven Cardiol 2014; 27:1-11
![Page 23: Bridging With Percutaneous Devices: Tandem Heart and Impella · Bridging With Percutaneous Devices: Tandem Heart and Impella DAVID A. BARAN, MD, FACC, FSCAI SYSTEM DIRECTOR, ADVANCED](https://reader033.fdocuments.in/reader033/viewer/2022051923/60113b9e924d623ac7210e23/html5/thumbnails/23.jpg)
USPELLA 2.5 Results
![Page 24: Bridging With Percutaneous Devices: Tandem Heart and Impella · Bridging With Percutaneous Devices: Tandem Heart and Impella DAVID A. BARAN, MD, FACC, FSCAI SYSTEM DIRECTOR, ADVANCED](https://reader033.fdocuments.in/reader033/viewer/2022051923/60113b9e924d623ac7210e23/html5/thumbnails/24.jpg)
USPELLA- Real World Registry Results, Impella 2.5
• No percutaneous MCS device is benign
• 9.5% vascular complication with surgical repair
• 10.3 % hemolysis
• 1.9 % CVA
![Page 25: Bridging With Percutaneous Devices: Tandem Heart and Impella · Bridging With Percutaneous Devices: Tandem Heart and Impella DAVID A. BARAN, MD, FACC, FSCAI SYSTEM DIRECTOR, ADVANCED](https://reader033.fdocuments.in/reader033/viewer/2022051923/60113b9e924d623ac7210e23/html5/thumbnails/25.jpg)
Impella
25
![Page 26: Bridging With Percutaneous Devices: Tandem Heart and Impella · Bridging With Percutaneous Devices: Tandem Heart and Impella DAVID A. BARAN, MD, FACC, FSCAI SYSTEM DIRECTOR, ADVANCED](https://reader033.fdocuments.in/reader033/viewer/2022051923/60113b9e924d623ac7210e23/html5/thumbnails/26.jpg)
IMPRESS- IAB vs Impella CP for Shock
• Multicenter, open label, randomized, N= 48
• IAB vs Impella CP, 1:1 randomization
• STEMI with immediate PCI
• CS as defined by SBP < 90 for 30 minutes or requirement for inotropes / pressors to maintain SBP > 90
• ALL Pts were VENTILATOR dependent to be enrolled!
• Informed consent WAIVED!
![Page 27: Bridging With Percutaneous Devices: Tandem Heart and Impella · Bridging With Percutaneous Devices: Tandem Heart and Impella DAVID A. BARAN, MD, FACC, FSCAI SYSTEM DIRECTOR, ADVANCED](https://reader033.fdocuments.in/reader033/viewer/2022051923/60113b9e924d623ac7210e23/html5/thumbnails/27.jpg)
BASELINE
• Systolic BP 81-84 mm Hg
• 85-92 % had cardiac arrest
• Time to ROSC 21-27 minutes mean
• Lactate 7.5-8.9 mean
• pH 7.14-7.17
• 60 + % had LVEF < 40
• 71-79 % had therapeutic hypothermia
![Page 28: Bridging With Percutaneous Devices: Tandem Heart and Impella · Bridging With Percutaneous Devices: Tandem Heart and Impella DAVID A. BARAN, MD, FACC, FSCAI SYSTEM DIRECTOR, ADVANCED](https://reader033.fdocuments.in/reader033/viewer/2022051923/60113b9e924d623ac7210e23/html5/thumbnails/28.jpg)
IMPRESS- IAB vs Impella CP for Shock
Zeymer and Thiele. JACC Jan 2017. p 288-290
![Page 29: Bridging With Percutaneous Devices: Tandem Heart and Impella · Bridging With Percutaneous Devices: Tandem Heart and Impella DAVID A. BARAN, MD, FACC, FSCAI SYSTEM DIRECTOR, ADVANCED](https://reader033.fdocuments.in/reader033/viewer/2022051923/60113b9e924d623ac7210e23/html5/thumbnails/29.jpg)
Impella With ECMO
Pappalardo et al. European J HF 2017; 19: 404-412
![Page 30: Bridging With Percutaneous Devices: Tandem Heart and Impella · Bridging With Percutaneous Devices: Tandem Heart and Impella DAVID A. BARAN, MD, FACC, FSCAI SYSTEM DIRECTOR, ADVANCED](https://reader033.fdocuments.in/reader033/viewer/2022051923/60113b9e924d623ac7210e23/html5/thumbnails/30.jpg)
Outcomes
![Page 31: Bridging With Percutaneous Devices: Tandem Heart and Impella · Bridging With Percutaneous Devices: Tandem Heart and Impella DAVID A. BARAN, MD, FACC, FSCAI SYSTEM DIRECTOR, ADVANCED](https://reader033.fdocuments.in/reader033/viewer/2022051923/60113b9e924d623ac7210e23/html5/thumbnails/31.jpg)
Gaudard et al. Critical Care 2015; 19:363
![Page 32: Bridging With Percutaneous Devices: Tandem Heart and Impella · Bridging With Percutaneous Devices: Tandem Heart and Impella DAVID A. BARAN, MD, FACC, FSCAI SYSTEM DIRECTOR, ADVANCED](https://reader033.fdocuments.in/reader033/viewer/2022051923/60113b9e924d623ac7210e23/html5/thumbnails/32.jpg)
N= 40 (Impella 5.0 device)
![Page 33: Bridging With Percutaneous Devices: Tandem Heart and Impella · Bridging With Percutaneous Devices: Tandem Heart and Impella DAVID A. BARAN, MD, FACC, FSCAI SYSTEM DIRECTOR, ADVANCED](https://reader033.fdocuments.in/reader033/viewer/2022051923/60113b9e924d623ac7210e23/html5/thumbnails/33.jpg)
Tandem Heart: Left Atrium to Femoral Artery Bypass
![Page 34: Bridging With Percutaneous Devices: Tandem Heart and Impella · Bridging With Percutaneous Devices: Tandem Heart and Impella DAVID A. BARAN, MD, FACC, FSCAI SYSTEM DIRECTOR, ADVANCED](https://reader033.fdocuments.in/reader033/viewer/2022051923/60113b9e924d623ac7210e23/html5/thumbnails/34.jpg)
TandemHeart vs IAB
Burkhoff et al, Am Heart Journal 2006; 152:469 e1-e8
![Page 35: Bridging With Percutaneous Devices: Tandem Heart and Impella · Bridging With Percutaneous Devices: Tandem Heart and Impella DAVID A. BARAN, MD, FACC, FSCAI SYSTEM DIRECTOR, ADVANCED](https://reader033.fdocuments.in/reader033/viewer/2022051923/60113b9e924d623ac7210e23/html5/thumbnails/35.jpg)
Tandem LA-FA Bypass Support vs IAB
• Prospective, randomized 12 site trial
• 42 patients but if a site had not placed Tandem they could “roll-in” a patient directly to Tandem
• Cardiogenic shock criteria: CI ≤ 2.2, PCWP ≥ 15 and hypoperfusion
• Could have IAB as long as still in CG shock
![Page 36: Bridging With Percutaneous Devices: Tandem Heart and Impella · Bridging With Percutaneous Devices: Tandem Heart and Impella DAVID A. BARAN, MD, FACC, FSCAI SYSTEM DIRECTOR, ADVANCED](https://reader033.fdocuments.in/reader033/viewer/2022051923/60113b9e924d623ac7210e23/html5/thumbnails/36.jpg)
Outcomes: 33 Randomized Patients
TH: 32 % death on support, 6/19 patients
No significant difference in Plasma Free HgB (hemolysis)
![Page 37: Bridging With Percutaneous Devices: Tandem Heart and Impella · Bridging With Percutaneous Devices: Tandem Heart and Impella DAVID A. BARAN, MD, FACC, FSCAI SYSTEM DIRECTOR, ADVANCED](https://reader033.fdocuments.in/reader033/viewer/2022051923/60113b9e924d623ac7210e23/html5/thumbnails/37.jpg)
• Single Center Experience• 117 pts Severe Refractory Cardiogenic Shock
• SBP < 90, CI < 2.0• Above hemodynamics ON IABP and pressors• 48 % of the patients were UNDERGOING CPR during insertion
of TH• Of these, 43 % (of the 48 %) survived 30 days
![Page 38: Bridging With Percutaneous Devices: Tandem Heart and Impella · Bridging With Percutaneous Devices: Tandem Heart and Impella DAVID A. BARAN, MD, FACC, FSCAI SYSTEM DIRECTOR, ADVANCED](https://reader033.fdocuments.in/reader033/viewer/2022051923/60113b9e924d623ac7210e23/html5/thumbnails/38.jpg)
Outcomes
![Page 39: Bridging With Percutaneous Devices: Tandem Heart and Impella · Bridging With Percutaneous Devices: Tandem Heart and Impella DAVID A. BARAN, MD, FACC, FSCAI SYSTEM DIRECTOR, ADVANCED](https://reader033.fdocuments.in/reader033/viewer/2022051923/60113b9e924d623ac7210e23/html5/thumbnails/39.jpg)
Next Generation?
![Page 40: Bridging With Percutaneous Devices: Tandem Heart and Impella · Bridging With Percutaneous Devices: Tandem Heart and Impella DAVID A. BARAN, MD, FACC, FSCAI SYSTEM DIRECTOR, ADVANCED](https://reader033.fdocuments.in/reader033/viewer/2022051923/60113b9e924d623ac7210e23/html5/thumbnails/40.jpg)
Possible Link
Johannson et al. Critical Care 2017; 21:25
![Page 41: Bridging With Percutaneous Devices: Tandem Heart and Impella · Bridging With Percutaneous Devices: Tandem Heart and Impella DAVID A. BARAN, MD, FACC, FSCAI SYSTEM DIRECTOR, ADVANCED](https://reader033.fdocuments.in/reader033/viewer/2022051923/60113b9e924d623ac7210e23/html5/thumbnails/41.jpg)
Why Does This Mechanism Exist?
• Cardiogenic shock is a hypercoagulable state
• Endothelial injury releases heparin and other molecules from the endothelial cells
• This anticoagulant effect balances the hypercoagulability of shock
![Page 42: Bridging With Percutaneous Devices: Tandem Heart and Impella · Bridging With Percutaneous Devices: Tandem Heart and Impella DAVID A. BARAN, MD, FACC, FSCAI SYSTEM DIRECTOR, ADVANCED](https://reader033.fdocuments.in/reader033/viewer/2022051923/60113b9e924d623ac7210e23/html5/thumbnails/42.jpg)
Shock Team
• Multidisciplinary team is essential in shock
• Team that works together can handle extreme stress of “crashing patients”
• Support early and aim to reverse hypoperfusion
• Vigilant monitoring and be prepared to escalate therapy
![Page 43: Bridging With Percutaneous Devices: Tandem Heart and Impella · Bridging With Percutaneous Devices: Tandem Heart and Impella DAVID A. BARAN, MD, FACC, FSCAI SYSTEM DIRECTOR, ADVANCED](https://reader033.fdocuments.in/reader033/viewer/2022051923/60113b9e924d623ac7210e23/html5/thumbnails/43.jpg)
Conclusions
• Complex spiral from insult to multiorgan dysfunction
• No one tool will suffice for all patients
• Risk / benefit profile of each device is unique and is weighed by the team when choosing a support device
• Regardless of device, the mortality is high and relatively unchanged
• Future advances will involve understanding the process of progression of shock to design inhibitors along with better pumps
![Page 44: Bridging With Percutaneous Devices: Tandem Heart and Impella · Bridging With Percutaneous Devices: Tandem Heart and Impella DAVID A. BARAN, MD, FACC, FSCAI SYSTEM DIRECTOR, ADVANCED](https://reader033.fdocuments.in/reader033/viewer/2022051923/60113b9e924d623ac7210e23/html5/thumbnails/44.jpg)
Thank You
![Page 45: Bridging With Percutaneous Devices: Tandem Heart and Impella · Bridging With Percutaneous Devices: Tandem Heart and Impella DAVID A. BARAN, MD, FACC, FSCAI SYSTEM DIRECTOR, ADVANCED](https://reader033.fdocuments.in/reader033/viewer/2022051923/60113b9e924d623ac7210e23/html5/thumbnails/45.jpg)
Which Device Do I Pick?
• Confidence-• Spider Sense that device will provide sufficient support
• Competence• Ability to rapidly place
• Changeability• Ability to change to another device if needed
• Capability• Inherent capability / flow / characteristics of the device